Anemia in the elderly-Clinical findings and impact on health

Critical Reviews in Oncology/Hematology

Volumn 58, Issue 2, 2006, Pages 156-165

  Balducci, L ^a   Ershler, W B ^b   Krantz, S ^c  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b Institute for Advanced Studies in Aging and Geriatric Medicine   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anemia; Comorbidities; Elderly; Erythropoietic agents; Erythropoietin

Indexed keywords

ANTHRACYCLINE; CAMPTOTHECIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPIPODOPHYLLOTOXIN; ERYTHROPOIETIN; FERRIC HYDROXIDE SUCROSE; FERRITIN; FERROUS SULFATE; FOLIC ACID; HEMOGLOBIN; HEPCIDIN; INTERLEUKIN 6; IRON; RECOMBINANT ERYTHROPOIETIN; TUMOR NECROSIS FACTOR ALPHA;

AGE DISTRIBUTION; AGED; ALZHEIMER DISEASE; ANEMIA; ANGINA PECTORIS; BLOOD CELL COUNT; BLOOD SMEAR; BONE MARROW DEPRESSION; BONE MARROW TOXICITY; CANCER; CANCER PAIN; CAUSE OF DEATH; CHRONIC DISEASE; CHRONIC KIDNEY FAILURE; COGNITIVE DEFECT; COMORBIDITY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; COST OF ILLNESS; CYANOCOBALAMIN DEFICIENCY; DEPRESSION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; ELDERLY CARE; ERYTHROCYTE COUNT; ERYTHROPOIESIS; FALLING; FATIGUE; FERRITIN BLOOD LEVEL; FOLIC ACID DEFICIENCY; HEADACHE; HEALTH STATUS; HEMATOCRIT; HEMATOPOIESIS; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; HUMAN; IRON BINDING CAPACITY; IRON DEFICIENCY; IRON THERAPY; MYELODYSPLASIA; POLYPHARMACY; PREVALENCE; QUALITY OF LIFE; RETICULOCYTE COUNT; REVIEW; RISK FACTOR;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANEMIA; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; FATIGUE; FEMALE; GERIATRIC ASSESSMENT; HEALTH CARE COSTS; HEALTH SERVICES FOR THE AGED; HUMANS; MALE; PREVALENCE; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 33748268309     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2005.09.003     Document Type: Review

References (104)

1. Hazzard W., Blass J., Ettinger W.J., Halter J., and Ouslander J. Principles of geriatric medicine. 4th ed. (1998), McGraw-Hill, New York
2. Izaks G.J., Westendorp RGJ, and Knook D.L. The definition of anemia in older persons. JAMA 281 18 (1999) 1714-1717
3. Ania B.J., Suman V.J., Fairbanks V.F., et al. Incidence of anemia in older people: an epidemiologic study in a well defined population. J Am Geriatr Soc 45 (1997) 825-831
4. Chaves P.H., Xue Q.L., Guralnik J.M., et al. What constitutes normal hemoglobin concentration in community-dwelling disabled older women?. J Am Geriatr Soc 52 (2004) 1811-1816
5. Guralnik J.M., Eisenstaedt R.S., Ferrucci L., et al. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood 104 (2004) 2263-2268
6. Gagnon D.R., Zhang T.J., Brand F.N., and Kannel W.B. Hematocrit and the risk of cardiovascular disease-the Framingham study: a 34-year follow-up. Am Heart J 127 3 (1994) 674-682
7. Marcantonio E.R., Goldman L., Orav E.J., Cook E.F., and Lee T.H. The association of intraoperative factors with the development of postoperative delirium. Am J Med 105 5 (1998) 380-384
8. London G.M., and Parfrey P.S. Cardiac disease in chronic uremia: pathogenesis. Adv Ren Replace Ther 4 (1997) 194-211
9. Foley R.N., Parfrey P.S., Harnet J.D., Kent G.M., Murray D.C., and Barre P.E. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kid Dis 28 1 (1996) 53-61
10. Wu W.-C., Rathore S., Wabg Y., Radford M.J., and Krumholz H.M. Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med 345 17 (2001) 1230-1236
11. Nissenson A.R. Epoetin and cognitive function. Am J Kid Dis 20 1 (1992) 21-24
12. Marsh J.T., Brown W.S., Wolcott D., et al. rHuEPO treatment improves brain and cognitive function of anemic dialysis patients. Kid Int 39 (1991) 155-163
13. Pickett J.L., Theberge D.C., Brown W.S., Schweitzer S.U., and Nissenson A.R. Normalizing hematocrit in dialysis patients improves brain function. Am J Kid Dis 33 6 (1999) 1122-1130
14. Cleeland C.S., Demetri G.D., Glaspy J., et al. Identifying hemoglobin level for optimal quality of life: results of an incremental analysis. Proc Am Soc Clin Oncol 18 (1999) 574A (Abstract 2215)
15. Gabrilove J.L., Cleeland C.S., Livingston R.B., Sarokhan B., Winer E., and Einhorn L.H. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19 11 (2001) 2875-2882
16. Littlewood T.J., Bajetta E., Nortier J.W., Vercammen E., and Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19 11 (2001) 2865-2874
17. Curt G.A., Breitbart W., Cella D., et al. Impact of cancer-related fatigue on the lives of patients: new findings from the fatigue coalition. Oncologist 5 5 (2000) 353-360
18. Balducci L., Hardy C.L., and Lyman G.H. Hemopoiesis and aging. In: Balducci L., and Extermann M. (Eds). Biological basis of geriatric oncology (2005), Springer, New York 111-134
19. Gabrilove J. Overview: erythropoiesis, anemia, and the impact of erythropoietin. Semin Hematol 37 4 Suppl 6 (2000) 1-3
20. Spivak J.L., Barnes D.C., Fuchs E., and Quin T.C. Serum immunoreactive erythopoietin in HIV-infected patients. JAMA 261 21 (1989) 3104-3107
21. Hardy J. Hardy's textbook of surgery (1988), Lippincott,Williams & Wilkins, Baltimore
22. Mansouri A., and Lipschitz D.A. Anemia in the elderly patient. Med Clin North Am 76 3 (1992) 619-630
23. Anía B.J., Suman V.J., Fairbanks V.F., and Melton III LJ. Prevalence of anemia in medical practice: community versus referral patients. Mayo Clin Proc 69 (1994) 730-735
24. Inelmen E.M., Alessio M.D., Gatto MRA, et al. Descriptive analysis of the prevalence of anemia in a randomly selected sample of elderly people living at home: some results of an Italian multicentric study. Aging Clin Exp Res 6 2 (1994) 81-89
25. Smith D.L. Anemia in the elderly. Am Fam Physic 62 7 (2000) 1565-1572
26. Garry P.J., Goodwin J.S., and Hunt W.C. Iron status and anemia in the elderly: new findings and a review of previous studies. J Am Geriatr Soc 31 7 (1983) 389-399
27. Tran K.H., Uddeen M.M., Taffet G.E., and Banez E. Erythropoietin regulation of hematopoiesis is preserved in healthy elderly people. Clin Res 41 2 (1993) 116A
28. Zauber P.N., and Zauber A.G. Hematologic data of healthy very old people. JAMA 257 16 (1987) 2181-2184
29. Joosten E., Pelemans W., Hiele M., Noyen J., Verhaeghe R., and Boogaerts M.A. Prevalence and causes of anaemia in a geriatric hospitalization population. Gerontology 38 (1992) 111-117
30. McKay P.J., Stott D.J., Holyoake T., Hendry A., MacDonald J.B., and Lucie N.P. Use of the erythrogram in the diagnosis of iron deficiency in elderly patients. Acta Haematol 89 (1993) 169-173
31. Weiss G., and Goodnough L.T. Anemia of chronic disease. N Engl J Med 352 (2005) 1011-1023
32. Abramson S.D., and Abramson N. 'Common' uncommon anemias. Am Fam Physic 59 (1999) 851-858
33. Carpenter M.A., Kendall R.G., O'Brien A.E., et al. Reduced erythropoietin response to anaemia in elderly patients with normocytic anaemia. Eur J Haematol 49 3 (1992) 119-121
34. Krantz S.B. Erythropoietin and the anaemia of chronic disease. Nephrol Dial Transpl 10 Suppl 2 (1995) 10-17
35. Ferrucci L., Corsi A., Lauretani F., et al. The origins of age-related pro-inflammatory state. Blood 105 (2005) 2294-2299
36. Cohen H.J., Harris F., and Pieper C.F. Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly. Am J Med 114 (2003) 180-18737
37. Cotroneo P., Ricerca B.M., Todaro L., et al. Blunted erythropoietin response to anemia in patients with Type 1 diabetes. Diab Metab Res Rev 16 (2000) 172-176
38. Volpe M., Tritto C., Testa U., et al. Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profiles. Am J Cardiol 74 (1994) 468-473
39. Cazzola M., Mercuriali F., and Brugnara C. Use of recombinant human erythropoietin outside the setting of uremia. Blood 89 12 (1997) 4248-4267
40. Goodnough L.T., Price H.T., and Parvin A.C. The endogenous erythropoietin response and the erythropoietic response to blood loss anemia: the effects of age and gender. J Lab Clin Med 126 1 (1995) 57-64
41. Powers J.S., Krantz S.B., Collins J.C., et al. Erythropoietin response to anemia as a function of age. J Am Geriatr Soc 39 (1991) 30-32
42. Kario K., Matsuo T., Kodama K., Nakao K., and Asada R. Reduced erythropoietin secretion in senile anemia. Am J Hematol 41 (1992) 252-257
43. Nafziger J., Pailla K., Luciani L., Andreux J.P., Saint-Jean O., and Casadevall N. Decreased erythropoietin responsiveness to iron deficiency in the elderly. Am J Hematol 43 (1993) 172-176
44. Metivier F., Marchais S.J., Guerin A.P., Pannier B., and London G.M. Pathophysiology of anaemia: focus on the heart and blood vessels. Nephrol Dial Transpl 15 Suppl 3 (2000) 14-18
45. Levin A., Singer J., Thompson C.R., Ross H., and Lewis M. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kid Dis 27 3 (1996) 347-354
46. Silverberg D.S., Wexler D., Blum M., et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 35 7 (2000) 1737-1744
47. Silverberg D.S., Wexler D., Sheps D., et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 37 7 (2001) 1775-1780
48. Beard C.M., Kokmen E., O'Brien P.C., Anía B.J., and Melton L.J. Risk of Alzheimer's disease among elderly patients with anemia: population-based investigations in Olmsted County, Minnesota. Ann Epidemiol 7 3 (1997) 219-224
49. Katz R.I., Beaston-Wimmer P., Parmelee P., Friedman E., and Lawton M.P. Failure to thrive in the elderly: exploration of the concept and delineation of psychiatric components. J Geriatr Psychiatr Neurol 6 (1993) 161-169
50. Nissenson R.A., Nimer D.S., and Wolcott L.D. Recombinant human erythropoietin and renal anemia: molecular biology, clinical efficacy, and nervous system effects. Ann Intern Med 114 (1991) 402-416
51. Cella D. The Functional assessment of cancer therapy-anemia (FACT-An) scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Haematol 34 3 Suppl 2 (1997) 13-19
52. Yellen S.B., Cella D.F., Webster K., Blendowski C., and Kaplan E. Measuring fatigue and other anemia-related symptoms with the functional assessment of cancer therapy (FACT) measurement system. J Pain Symptom Manage 13 2 (1997) 63-74
53. Khayat D. Is anemia a problem for European cancer patients and treating oncologists?. Semin Oncol 2 Suppl 4 (2000) 9-11
54. Liao S., and Ferrell B. Fatigue in an older population. J Am Geriatr Soc 48 (2000) 426-430
55. Herndon J.G., Helmick C.G., Sattin R.W., Stevens J.A., DeVito C., and Wingo P.A. Chronic medical conditions and risk of fall injury events at home in older adults. J Am Geriatr Soc 45 (1997) 739-743
56. Kamenetz Y., Belooseky Y., Zelzer C., et al. Relationship between routine hematological parameters, serum IL-3, IL-6 and erythropoietin and mild anemia and degree of function in the elderly. Aging Clin Exp Res 10 1 (1998) 32-38
57. Pierelli L., Perillo A., Greggi S., et al. Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel, and cisplatin combination chemotherapy: results of a randomized comparison. J Clin Oncol 17 4 (1999) 1288-1295
58. Ratain M.J., Schilsky R.L., Choi K.E., et al. Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability. Clin Pharmacol Ther 45 3 (1988) 226-233
59. Silber J.H., Fridman M., et al. First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy. J Clin Oncol 16 7 (1998) 2392-2400
60. Extermann M., Chen H., Cantor A.B., et al. Predictors of toxicity from chemotherapy in older patients: a prospective pilot study. Proc Am Soc Clin Oncol 19 (2000) 617a
61. Melton L., Khosla S., Crowson C.S., et al. Epidemiology of sarcopenia. J Am Geriatr Soc 48 (2000) 625-630
62. Astani A., Smith R.C., and Allen B.J. The predictive value of body proteins for chemotherapy induced toxicity. Cancer 88 (2000) 898-903
63. Glaspy J., Singh Jajeda J., Justice G., et al. Randomized, active-controlled phase I/II dose escalation study of novel erythropoiesis stimulating protein (NESP) in solid tumour patients. Ann Oncol 11 Suppl 4 (2000) 146
64. Pirker R., Vansteenkiste J., Gately J., Yates P., Colowick A., and Musil J. A phase 3, double-blind, placebo-controlled, randomized study of novel erythropoiesis stimulating protein (NESP) in patients undergoing platinum treatment for lung cancer. Proc Am Soc Clin Oncol 20 (2001) 394a Abstract 1572
65. Fried L.P., Storer D.J., King D.E., and Lodder F. Diagnosis of illness presentation in the elderly. J Am Geriatr Soc 39 2 (1991) 117-123
66. Balducci L. Perspectives on quality of life of older patients with cancer. Drugs Aging 4 4 (1994) 313-324
67. Ahluwalia N., Lammi-Keefe C.J., Bendel R.B., Morse E.E., Beard J.L., and Haley N.R. Iron deficiency and anemia of chronic disease in elderly women: a discriminate-analysis approach for differentiation. Am J Clin. Nutr 61 (1995) 590-596
68. Hansen T., and Hansen N. Serum ferritin as an indicator of iron responsiveness anaemia in patients with rheumatoid arthritis. Ann Rheum Dis 45 (1986) 596-602
69. Baynes R., and Cook J. Current issues in iron deficiency. Curr Opin Hematol 3 (1996) 145-149
70. Daly P.M. Anemia in the elderly. Am Fam Physic 39 3 (1989) 129-136
71. Charytan C., Levin N., Al-Saloum M., Hafeez T., Gagnon S., and Van Wyck D.B. Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial. Am J Kid Dis 37 2 (2001) 300-307
72. Murphy P.T., and Hutchinson R.M. Identification and treatment of anaemia in older patients. Drugs Aging 4 2 (1994) 113-127
73. Walsh J.R. Hematologic problems. In: Cassel C.K., Cohen H.J., and Larson E.B. (Eds). Geriatric medicine (1997), Springer-Verlag, New York 627-636
74. Lipschitz D.A. The effect of age on hematopoiesis and the work up of anemia in the elderly. Am J Hematol (1999) 504-509
75. Glaspy J., Singh Jadeja J., Justice G., et al. A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy. Br J Cancer 84 1 (2001) 17-23
76. Smith R., Jaiyesimi I., Meza L., et al. Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer. Br J Cancer 84 Suppl 1 (2001) 24-30
77. Smith R., Meza L., Tchekmedyian S., et al. Open-label, phase I/II dose escalation study of NESP in patients with chronic anemia of cancer. Proc Am Soc Clin Oncol 20 (2001) 394a
78. Heatherington A., Rovetti R., Glaspy J., and Colowick A. Predictability of pharmacokinetic properties of NESP administered once every 3 weeks in patients with nonmyeloid malignancies receiving cyclic chemotherapy. Proc Am Soc Clin Oncol 20 (2001) 119a
79. Heatherington A., Schuller J., and Mercer A. Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report. Br J Cancer 84 Suppl 1 (2001) 11-16
80. Hedanus M., Hansen S., Dewey C., Watson D., Colowick A., and Osterborg A.A. Randomized, placebo-controlled, phase II, dose-finding study of novel erythropoiesis stimulating protein (NESP) in patients with lymphoproliferative malignancies. Proc Am Soc Clin Oncol 20 (2001) 393a
81. Kotasek D., Berg R., Poulsen E., and Colowick A. Randomized, double-blind, placebo controllled, phase I/II dose finding study of Aranesp administered once every three weeks in solid tumor patients. Blood 11 Part 1 (2000) 294a
82. Demetri G.D., Kris M., Wade J., Degos L., Cella D., and Procrit Study Group. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 16 10 (1998) 3412-3425
83. Demetri G.D. Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy. Br J Cancer 84 Suppl 1 (2001) 31-37
84. Glaspy J., Bukowski R., Steinberg D., Taylor C., Tchekmedyian S., Vadhan-Raj S., and Procrit Study Group. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 15 3 (1997) 1218-1234
85. Eschbach J.W., Downing M.R., Egrie J.C., Browne J.K., and Adamson J.W. USA multicenter clinical trial with recombinant human erythropoietin. Contrib Nephrol 76 (1989) 160-165
86. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Br Med J 1990;300:573-78
87. Sundal E., and Kaeser U. Correction of anaemia of chronic renal failure with recombinant human erythropoietin: safety and efficacy of one year's treatment in a European multicentre study of 150 haemodialysis-dependent patients. Nephrol Dial Transpl 4 11 (1989) 979-987
88. Teruel J.L., Pascual J., Jimenez M., et al. Hemodynamic changes in hemodialyzed patients during treatment with recombinant human erythropoietin. Nephron 58 2 (1991) 135-137
89. MacDougall I., Lewis N., Saunders M., et al. Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin. Lancet 335 (1990) 489-493
90. Wizemann V., Kaufmann J., and Kramer W. Effect of erythropoietin on ischemia tolerance in anemic hemodialysis patients with confirmed coronary artery disease. Nephron 62 2 (1992) 161-165
91. Low-Friedrich I., Grutzmacher P., Marz W., Bergmann M., and Schoeppe W. Therapy with recombinant human erythropoietin reduces cardiac size and improves heart function in chronic hemodialysis patients. Am J Nephrol 11 1 (1991) 54-60
92. Pascual J., Teruel J.L., Moya J.L., Liano F., Jimenez-Mena M., and Ortuno J. Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: a prospective study. Clin Nephrol 35 6 (1991) 280-287
93. Mayer G., Thum J., Cada E., Stummvoll K., and Graf H. Working capacity is increased following recombinant human erythropoietin treatment. Kid Int 34 (1988) 525-528
94. Barany P., Freyschuss U., Pettersson E., and Bergstrom J. Treatment of anaemia in haemodialysis patients with erythropoietin: long-term effects on exercise capacity. Clin Sci 84 4 (1993) 441-447
95. McMahon L.P., McKenna M.J., Sangkabutra T., et al. Physical performance and associated electrolyte changes after haemoglobin normalization: a comparative study in haemodialysis patients. Nephrol Dial Transpl 14 5 (1999) 1182-1187
96. Delano B. Improvements in quality of life following treatment with r-HuEPO in anemic hemodialysis patients. Am J Kid Dis 2 Suppl.1 (1989) 14-18
97. Evans R., Rader B., and Manninem D. The quality of life of hemodialysis recipients treated with recombinant human erythropoetin. JAMA 263 6 (1990) 825-830
98. Barany P., Pettersson E., and Konarski-Svensson. Long-term effects on quality of life in haemodialysis patients of correction of anaemia with erythropoietin. Nephrol Dial Transpl 8 (1993) 426-432
99. Macdougall I.C. Novel erythropoiesis stimulating protein. Semin Nephrol 20 4 (2000) 375-381
100. Van Wyck D., Stivelman J., Ruiz J., Kirlin L., Katz M., and Ogden D. Iron status in patients receiving erythropoietin for dialysis-associated anemia. Kid Int 35 (1989) 712-716
101. Van Wyck D. Management of early renal anaemia: diagnostic work-up, iron therapy, epoetin therapy. Nephrol Dial Transpl 15 Suppl 3 (2000) 36-39
102. Ershler W., Artz A., and Kandahari M. Treatment with recombinant erythropoietin in ambulatory elderly. J Am Geriatr Soc 49 (2001) 1396-1397
103. Valderrabano F. Quality of life benefits of early anaemia treatment. Nephrol Dial Transpl 15 Suppl 3 (2000) 23-28
104. Moreno F., Sanz-Guajardo D., Lopez-Gomex J.M., Jofre R., and Valderrabano F. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. J Am Soc Nephrol 11 (2000) 335-342